Atopic Dermatitis

High Patient Burden With Moderate-to-Severe Atopic Dermatitis

July 06, 2018

Many patients with moderate/severe atopic dermatitis have inadequate disease control

Positive Results for Dupilumab in Teen Atopic Dermatitis Trial

By May 16, 2018

The primary endpoint was the proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) at Week 16.

No Clinical Benefit Seen for Bath Emollients in Childhood Eczema

May 03, 2018

POEM scores didn't meet minimal clinically important difference after adjustment for confounders

Oral JAK1 Inhibitor Gets Breakthrough Tx Designation for Atopic Dermatitis

By February 15, 2018

In December, a Phase 3, randomized, double-blind, placebo-controlled trial (JADE) was initiated to evaluate the safety and efficacy of PF-04965842 in 375 patients aged ≥12 years with moderate to severe AD.

Methotrexate, Azathioprine Examined in Moderate-to-Severe Atopic Dermatitis

December 26, 2017

For up to five years as maintenance treatments for moderate-to-severe atopic dermatitis

Dupixent Improves Disease Severity, Skin Clearing in Atopic Dermatitis

By September 20, 2017

The data indicated 59% of patients given Dupixent weekly with topical corticosteroids and 63% of patients given Dupixent every 2 weeks with topical corticosteroids achieved EASI-75 vs. 30% of patients given placebo with topical corticosteroids (P<0.0001).

Which Medications Are Prescribed Most Often for Atopic Dermatitis?

By August 10, 2017

Male patients exhibited the highest rates of oral steroid prescriptions.

Dupixent Approved for Moderate-to-Severe Atopic Dermatitis

By March 28, 2017

Dupixent, a human monoclonal antibody, works by inhibiting the overactive signaling of IL-4 and IL-13 proteins, which are believed to play a major role in the persistent inflammation in atopic dermatitis.